B7-H3-targeted CAR-T cell therapy for solid tumors

References

• Suh W-K, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4(9):899–906. doi:10.1038/ni967.
   PubMed Web of Science ®Google Scholar
• Kontos F, Michelakos T, Kurokawa T, et al. B7-H3: An Attractive Target for Antibody-based Immunotherapy. Clin Cancer Res. 2021;27(5):1227–1235. doi:10.1158/1078-0432.CCR-20-2584.
   PubMed Web of Science ®Google Scholar
• Zhang G, Hou J, Shi J, et al. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology. 2008;123(4):538–546. doi:10.1111/j.1365-2567.2007.02723.x.
   PubMed Web of Science ®Google Scholar
• Vigdorovich V, Ramagopal UA, Lázár-Molnár E, et al. Structure and T cell inhibition properties of B7 family member, B7-H3. Structure. 2013;21(5):707–717. doi:10.1016/j.str.2013.03.003.
   PubMed Web of Science ®Google Scholar
• Sun J, Chen L-j, Zhang G-b, et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 2010;59(8):1163–1171. doi:10.1007/s00262-010-0841-1.
   PubMed Web of Science ®Google Scholar
• Benzon B, Zhao SG, Haffner MC, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 2017;20(1):28–35. doi:10.1038/pcan.2016.49.
   PubMed Web of Science ®Google Scholar
• ZHAO XIN, LI DE-C, ZHU X-G, et al. B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med. 2013;31(2):283–291. doi:10.3892/ijmm.2012.1212.
   PubMed Web of Science ®Google Scholar
• Zhang S-S, Tang J, Yu S-Y, et al. Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma. Oncol Lett. 2015;10(2):1063–1068. doi:10.3892/ol.2015.3274.
   PubMed Web of Science ®Google Scholar
• Xu YH, et al. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J. 2010;31(9):980–986.
   PubMed Web of Science ®Google Scholar
• Liao H, Ding M, Zhou N, et al. B7H3 promotes the epithelialmesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway. Mol Med Rep. 2022;25(3):79. doi:10.3892/mmr.2022.12595.
   Web of Science ®Google Scholar
• Li Y, Yang X, Wu Y, et al. B7-H3 promotes gastric cancer cell migration and invasion. Oncotarget. 2017;8(42):71725–71735. doi:10.18632/oncotarget.17847.
   PubMedGoogle Scholar
• Cheng R, Chen Y, Zhou H, et al. B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma. APMIS. 2018;126(5):396–402. doi:10.1111/apm.12837.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang L, Qian J, et al. Expression characteristic of 4Ig B7-H3 and 2Ig B7-H3 in acute myeloid leukemia. Bioengineered. 2021;12(2):11987–12002. doi:10.1080/21655979.2021.2001182.
   PubMed Web of Science ®Google Scholar
• Dondero A, Morini M, Cangelosi D, et al. Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants. J Immunother Cancer. 2021;9(4):e002293. doi:10.1136/jitc-2020-002293.
   PubMed Web of Science ®Google Scholar
• Chen C, Wang Y, Zhong K, et al. Frequent B7-H3 overexpression in craniopharyngioma. Biochem Biophys Res Commun. 2019;514(2):379–385. doi:10.1016/j.bbrc.2019.04.142.
   PubMed Web of Science ®Google Scholar
• Bachawal SV, Jensen KC, Wilson KE, et al. Breast cancer detection by B7-H3-targeted ultrasound molecular imaging. Cancer Res. 2015;75(12):2501–2509. doi:10.1158/0008-5472.CAN-14-3361.
   PubMed Web of Science ®Google Scholar
• Zang X, Sullivan PS, Soslow RA, et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 2010;23(8):1104–1112. doi:10.1038/modpathol.2010.95.
   PubMed Web of Science ®Google Scholar
• Li Y, Cai Q, Shen X, et al. Overexpression of B7-H3 is associated with poor prognosis in laryngeal cancer. Front Oncol. 2021;11:759528.
   PubMedGoogle Scholar
• Leitner J, Klauser C, Pickl WF, et al. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol. 2009;39(7):1754–1764. doi:10.1002/eji.200839028.
   PubMed Web of Science ®Google Scholar
• Kobori H, Hashiguchi M, Piao J, et al. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites. Immunology. 2010;130(3):363–373. doi:10.1111/j.1365-2567.2009.03236.x.
   PubMed Web of Science ®Google Scholar
• Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–3431. doi:10.1158/1078-0432.CCR-15-2428.
   PubMed Web of Science ®Google Scholar
• Castellanos JR, Purvis IJ, Labak CM, et al. B7-H3 role in the immune landscape of cancer. Am J Clin Exp Immunol. 2017;6(4):66–75.
   PubMed Web of Science ®Google Scholar
• Li H, Yang Z, Yang X, et al. LINC01123 promotes immune escape by sponging miR-214-3p to regulate B7-H3 in head and neck squamous-cell carcinoma. Cell Death Dis. 2022;13(2):109. doi:10.1038/s41419-022-04542-0.
   Web of Science ®Google Scholar
• Amori G, Sugawara E, Shigematsu Y, et al. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):767–774. doi:10.1038/s41391-021-00331-6.
   PubMed Web of Science ®Google Scholar
• Ye Z, Zheng Z, Li X, et al. B7-H3 overexpression predicts poor survival of cancer patients: a meta-analysis. Cell Physiol Biochem. 2016;39(4):1568–1580. doi:10.1159/000447859.
   PubMedGoogle Scholar
• Liu Z, Zhang W, Phillips JB, et al. Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation. Oncogene. 2019;38(1):88–102. doi:10.1038/s41388-018-0407-9.
   PubMed Web of Science ®Google Scholar
• Dong P, Xiong Y, Yue J, et al. B7H3 as a promoter of metastasis and promising therapeutic target. Front Oncol. 2018;8:264.
   PubMed Web of Science ®Google Scholar
• Shi T, Ma Y, Cao L, et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019;10(4):308. doi:10.1038/s41419-019-1549-6.
   PubMed Web of Science ®Google Scholar
• Modak S, Kramer K, Gultekin SH, et al. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 2001;61(10):4048–4054.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Cheng M, Zhao Q, et al. Humanized affinity-matured monoclonal antibody 8h9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. J Biol Chem. 2015;290(50):30018–30029. doi:10.1074/jbc.M115.679852.
   PubMed Web of Science ®Google Scholar
• Bailey K, Pandit-Taskar N, Humm JL, et al. Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. J Neurooncol. 2019;143(1):101–106. doi:10.1007/s11060-019-03139-6.
   PubMed Web of Science ®Google Scholar
• Loo D, Alderson RF, Chen FZ, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012;18(14):3834–3845. doi:10.1158/1078-0432.CCR-12-0715.
   PubMed Web of Science ®Google Scholar
• Kendsersky NM, Lindsay J, Kolb EA, et al. The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models. Clin Cancer Res. 2021;27(10):2938–2946. doi:10.1158/1078-0432.CCR-20-4221.
   PubMed Web of Science ®Google Scholar
• Powderly J, Cote G, Flaherty K, et al. Interim results of an ongoing phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3- expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunother Cancer. 2015;3(Suppl 2):O8. doi:10.1186/2051-1426-3-S2-O8.
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Prawira A, Antonia S, et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. J Immunother Cancer. 2022;10(4):e004424. doi:10.1136/jitc-2021-004424.
   PubMed Web of Science ®Google Scholar
• Jayaraman J, Mellody MP, Hou AJ, et al. CAR-T design: elements and their synergistic function. Ebiomedicine. 2020;58:102931. doi:10.1016/j.ebiom.2020.102931.
   PubMed Web of Science ®Google Scholar
• Bailey SR, Maus MV. Gene editing for immune cell therapies. Nat Biotechnol. 2019;37(12):1425–1434. doi:10.1038/s41587-019-0137-8.
   PubMed Web of Science ®Google Scholar
• Landoni E, Fucá G, Wang J, et al. Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling. Cancer Immunol Res. 2021;9(4):441–453. doi:10.1158/2326-6066.CIR-20-0451.
   PubMed Web of Science ®Google Scholar
• Xu C, Bai Y, An Z, et al. IL-13Ralpha2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma. Mol Ther Oncolytics. 2022;24:443–451. doi:10.1016/j.omto.2022.01.002.
   PubMed Web of Science ®Google Scholar
• Smith EL, Staehr M, Masakayan R, et al. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol Ther. 2018;26(6):1447–1456. doi:10.1016/j.ymthe.2018.03.016.
   PubMed Web of Science ®Google Scholar
• Jonnalagadda M, Mardiros A, Urak R, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther. 2015;23(4):757–768. doi:10.1038/mt.2014.208.
   PubMed Web of Science ®Google Scholar
• Qin L, Lai Y, Zhao R, et al. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. J Hematol Oncol. 2017;10(1):68. doi:10.1186/s13045-017-0437-8.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Bajgain P, Sukumaran S, et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016;5(12):e1253656. doi:10.1080/2162402X.2016.1253656.
   PubMed Web of Science ®Google Scholar
• Makita S, Yoshimura K, Tobinai K. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci. 2017;108(6):1109–1118. doi:10.1111/cas.13239.
   PubMed Web of Science ®Google Scholar
• Wilkie S, Picco G, Foster J, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180(7):4901–4909. doi:10.4049/jimmunol.180.7.4901.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Riddell SR. Engineering CAR-T cells: Design concepts. Trends Immunol. 2015;36(8):494–502. doi:10.1016/j.it.2015.06.004.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Sommermeyer D, Kosasih PL, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3(2):125–135. doi:10.1158/2326-6066.CIR-14-0127.
   PubMed Web of Science ®Google Scholar
• James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028–7038. doi:10.4049/jimmunol.180.10.7028.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Lupo-Stanghellini M-T, Kosasih PL, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19(12):3153–3164. doi:10.1158/1078-0432.CCR-13-0330.
   PubMed Web of Science ®Google Scholar
• Almasbak H, et al. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 2015;22(5):391–403.
   PubMed Web of Science ®Google Scholar
• Heitzeneder S, Bosse KR, Zhu Z, et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell. 2022;40(1):53–69.e9. doi:10.1016/j.ccell.2021.12.005.
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Hawkins RE, Bagley S, et al. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol. 2010;184(12):6938–6949. doi:10.4049/jimmunol.0901766.
   PubMed Web of Science ®Google Scholar
• Guedan S, Posey AD, Shaw C, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018;3(1):e96976. doi:10.1172/jci.insight.96976.
   Web of Science ®Google Scholar
• Zhang T, Wu MR, Sentman CL. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol. 2012;189(5):2290–2299. doi:10.4049/jimmunol.1103495.
   PubMed Web of Science ®Google Scholar
• Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of hpv-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733–1741. doi:10.1158/0008-5472.CAN-12-2384.
   PubMed Web of Science ®Google Scholar
• Alabanza L, Pegues M, Geldres C, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017;25(11):2452–2465. doi:10.1016/j.ymthe.2017.07.013.
   PubMed Web of Science ®Google Scholar
• Muller YD, Nguyen DP, Ferreira LMR, et al. The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28. Front Immunol. 2021;12:639818.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Rietberg SP, Sotillo E, et al. Tuning the Antigen Density Requirement for CAR T-cell Activity. Cancer Discov. 2020;10(5):702–723. doi:10.1158/2159-8290.CD-19-0945.
   PubMed Web of Science ®Google Scholar
• Condomines M, Arnason J, Benjamin R, et al. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS ONE. 2015;10(6):e0130518. doi:10.1371/journal.pone.0130518.
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581–590. doi:10.1038/nm.3838.
   PubMed Web of Science ®Google Scholar
• Weinkove R, George P, Dasyam N, et al. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol. 2019;8(5):e1049. doi:10.1002/cti2.1049.
   PubMed Web of Science ®Google Scholar
• Wu W, Zhou Q, Masubuchi T, et al. Multiple signaling roles of CD3epsilon and its application in CAR-T cell therapy. Cell. 2020;182(4):855–871 e23. doi:10.1016/j.cell.2020.07.018.
   PubMed Web of Science ®Google Scholar
• Li W, Qiu S, Chen J, et al. Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy. Immunity. 2020;53(2):456–470.e6. doi:10.1016/j.immuni.2020.07.011.
   PubMed Web of Science ®Google Scholar
• Tang X, Zhao S, Zhang Y, et al. B7-H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncolytics. 2019;14:279–287. doi:10.1016/j.omto.2019.07.002.
   PubMed Web of Science ®Google Scholar
• Nehama D, Di Ianni N, Musio S, et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. Ebiomedicine. 2019;47:33–43. doi:10.1016/j.ebiom.2019.08.030.
   PubMed Web of Science ®Google Scholar
• Tang X, Wang Y, Huang J, et al. Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma. Signal Transduct Target Ther. 2021;6(1):125.
   PubMed Web of Science ®Google Scholar
• Long C, Li G, Zhang C, et al. B7-H3 as a target for CAR-T cell therapy in skull base chordoma. Front Oncol. 2021;11:659662. doi:10.3389/fonc.2021.659662.
   PubMed Web of Science ®Google Scholar
• Liu J, Yang S, Cao B, et al. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021;14(1):21. doi:10.1186/s13045-020-01024-8.
   PubMed Web of Science ®Google Scholar
• Zhu L, Liu J, Zhou G, et al. Remodeling of tumor microenvironment by tumor-targeting nanozymes enhances immune activation of CAR T cells for combination therapy. Small. 2021;17(43):2102624. doi:10.1002/smll.202102624.
   PubMed Web of Science ®Google Scholar
• Yang M, Tang X, Zhang Z, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumours. Theranostics. 2020;10(17):7622–7634. doi:10.7150/thno.43991.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jiang C, Liu Z, et al. B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors. Mol Ther Oncolytics. 2020;17:180–189. doi:10.1016/j.omto.2020.03.019.
   PubMed Web of Science ®Google Scholar
• Lei X, Ou Z, Yang Z, et al. A pan-histone deacetylase inhibitor enhances the antitumor activity of B7-H3-specific CAR T cells in solid tumors. Clin Cancer Res. 2021;27(13):3757–3771. doi:10.1158/1078-0432.CCR-20-2487.
   PubMed Web of Science ®Google Scholar
• Du H, Hirabayashi K, Ahn S, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35(2):221–237 e8. doi:10.1016/j.ccell.2019.01.002.
   PubMed Web of Science ®Google Scholar
• Huang B, Luo L, Wang J, et al. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. Oncoimmunology. 2020;9(1):1684127. doi:10.1080/2162402X.2019.1684127.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019;25(8):2560–2574. doi:10.1158/1078-0432.CCR-18-0432.
   PubMed Web of Science ®Google Scholar
• Talbot LJ, Chabot A, Funk A, et al. A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3-CAR T cells. Front Immunol. 2021;12:691741. doi:10.3389/fimmu.2021.691741.
   PubMed Web of Science ®Google Scholar
• Theruvath J, Sotillo E, Mount CW, et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat Med. 2020;26(5):712–719. doi:10.1038/s41591-020-0821-8.
   PubMed Web of Science ®Google Scholar
• Zhang Y, He L, Sadagopan A, et al. Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T Cells. Mol Cancer Ther. 2021;20(3):577–588. doi:10.1158/1535-7163.MCT-20-0446.
   PubMed Web of Science ®Google Scholar
• Tang X, Liu F, Liu Z, et al. Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma. Clin Transl Immunology. 2020;9(6):e1137. doi:10.1002/cti2.1137.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in. Neuro-Oncology, 2021. 2011;20, pg iv1, 2018(23(3):508–522.
   Google Scholar
• Digregorio M, Coppieters N, Lombard A, et al. The expression of B7-H3 isoforms in newly diagnosed glioblastoma and recurrence and their functional role. Acta Neuropathol Commun. 2021;9(1):59. doi:10.1186/s40478-021-01167-w.
   PubMed Web of Science ®Google Scholar
• Yim J, Koh J, Kim S, et al. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer. Eur J Cancer. 2020;133:74–85. doi:10.1016/j.ejca.2020.03.033.
   PubMed Web of Science ®Google Scholar
• Zhu L, Liu J, Zhou G, et al. Remodeling of tumor microenvironment by tumor-targeting nanozymes enhances immune activation of CAR T Cells for combination therapy. Small. 2021;17(43):e2102624. doi:10.1002/smll.202102624.
   PubMed Web of Science ®Google Scholar
• Udaka YT, Packer RJ. Pediatric brain tumors. Neurol Clin. 2018;36(3):533–556. doi:10.1016/j.ncl.2018.04.009.
   PubMed Web of Science ®Google Scholar
• Schultz LM, Majzner R, Davis KL, et al. New developments in immunotherapy for pediatric solid tumors. Curr Opin Pediatr. 2018;30(1):30–39.
   PubMed Web of Science ®Google Scholar
• Nguyen P, Okeke E, Clay M, et al. Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR.CD28zeta T cells. Mol Ther Oncolytics. 2020;18:202–214. doi:10.1016/j.omto.2020.06.018.
   PubMed Web of Science ®Google Scholar
• Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. doi:10.1016/j.bpobgyn.2016.08.006.
   PubMed Web of Science ®Google Scholar
• Cai D, Li J, Liu D, et al. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol. 2020;17(3):227–236. doi:10.1038/s41423-019-0305-2.
   PubMed Web of Science ®Google Scholar